Late-breaking one-year VERITAS study results were presented at the Transcatheter Cardiovascular Therapeutics conference and simultaneously published in JACC: Cardiovascular Interventions; data show the device achieved
SonicForce is an investigational coronary intravascular lithotripsy (IVL) system that uses acoustic pressure waves, similar to those used to break up kidney stones, to crack calcium in coronary arteries and restore
CROWN-MV trial will evaluate the safety and effectiveness of investigational Cephea mitral valve replacement deviceAbbott's Cephea is designed to provide a new, minimally invasive option for treating mitral valve
Powered by whole-genome sequencing and MAESTRO* technology, the next-generation Oncodetect test takes a distinct approach to MRD, tracking up to 5,000 patient-specific variants with a limit of detection below one part
Beta-CORRECT study shows a 10.6-fold higher risk of recurrence, reinforcing the prognostic value of molecular residual disease (MRD) testing1Building on its leadership in colorectal cancer screening with the Cologuard®
VANCOUVER, BC, Oct. 21, 2026 /CNW/ -- Stock Preachers News Commentary - Three sessions into the week, growth and small caps are setting the pace. The Nasdaq Composite jumped 1.04% on the day and is up 2.14% for the week
Third-quarter reported sales growth of 14.5 percent; comparable sales growth of 7.0 percentThird-quarter GAAP diluted EPS of $0.53; adjusted diluted EPS of $1.42Expands portfolio with key new product approvalsABBOTT
Separation will unlock potential of both companies to pursue distinct growth and value-creation strategiesThe new Nutrition company will be a global leader in the rapidly growing healthy nutrition market, with a
New powder combines 30 grams of high‑quality protein to help build muscle tissue,† 5 grams of creatine monohydrate to support muscle recovery‡* and 3 grams of calcium HMB (beta-hydroxy-beta-methylbutyrate) to help
For the first time, U.S. CardioMEMS patients will be able to view pulmonary artery pressure (PAP) readings and receive personalized medication updates through the CardioGuide HF AppRising PAP can signal worsening heart
ABBOTT PARK, Ill., Sept. 30, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its third-quarter 2026 financial results on Wednesday, Oct. 21, before the market opens.
The announcement will be followed by a live
Only Abbott offers a complete screening solution combining end-to-end support with both stool- and blood-based colorectal cancer screening options, giving healthcare providers more ways to help eligible patients get
ABBOTT PARK, Ill., Sept. 17, 2026 /PRNewswire/ -- The board of directors of Abbott (NYSE:ABT) today declared a quarterly common dividend of 63 cents per share.
This marks the 411th consecutive quarterly dividend to be
Abbott's Volt™ Pulsed Field Ablation System is the next generation of cardiac ablation technology built on a distinctive balloon-in-basket design to treat people with heart rhythm disorders such as atrial
